The company lacks any commercial revenue, resulting in consistent operating losses that reached $5.9 million in 2026Q1.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 2.52M | 3.36M |
| Revenue Growth % | - | - | - | - | - | -100% | -24.99% | - |
| Cost of Goods Sold | 19K | 0 | 0 | 0 | 0 | 0 | 0 | 1K |
| COGS % of Revenue | - | - | - | - | - | - | - | 0.03% |
| Gross Profit | -19K | 0 | 0 | 0 | 0 | 0 | 2.52M | 3.36M |
| Gross Margin % | - | - | - | - | - | - | 100% | 99.97% |
| Gross Profit Growth % | - | - | - | - | - | -100% | -24.97% | - |
| Operating Expenses | 18.26M | 12.8M | -72.98M | 348.09M | 48.43M | 65.85M | 18.91M | 57.32M |
| OpEx % of Revenue | - | - | - | - | - | - | 750.83% | 1707.54% |
| Selling, General & Admin | 12.97M | 12.21M | 13.64M | 19.79M | 13.68M | 11.15M | 11.59M | 46.04M |
| SG&A % of Revenue | - | - | - | - | - | - | 460.17% | 1371.37% |
| Research & Development | 5.3M | 4.09M | 14.18M | 33.05M | 34.75M | 25.73M | 7.32M | 4.81M |
| R&D % of Revenue | - | - | - | - | - | - | 290.67% | 143.4% |
| Other Operating Expenses | -11K | -3.5M | -100.81M | 295.25M | 0 | 28.97M | 0 | 6.47M |
| Operating Income | -18.28M | -12.8M | 72.98M | -348.09M | -48.43M | -65.85M | -16.39M | -53.97M |
| Operating Margin % | - | - | - | - | - | - | -650.83% | -1607.57% |
| Operating Income Growth % | - | -117.54% | 120.97% | -618.76% | 26.45% | -301.8% | 69.63% | - |
| EBITDA | -18.2M | -12.72M | 73.08M | -347.99M | -48.36M | -65.84M | -15.51M | -53.09M |
| EBITDA Margin % | - | - | - | - | - | - | -616.08% | -1581.5% |
| EBITDA Growth % | -112.4% | -117.41% | 121% | -619.56% | 26.55% | -324.44% | 70.78% | - |
| D&A (Non-Cash Add-back) | 78K | 78K | 97K | 99K | 68K | 3K | 875K | 875K |
| EBIT | -18.29M | -16.3M | -27.82M | -52.84M | -48.43M | -36.88M | -16.39M | -48.37M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | -15K | -6.75M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 720K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 15K | 7.47M |
| Other Income/Expense | -41.83M | -26.42M | -30.98M | -36.55M | -4.13M | 10.21M | -16.52M | 199.64M |
| Pretax Income | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M | -32.91M | 145.67M |
| Pretax Margin % | - | - | - | - | - | - | -1307.11% | 4339.29% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.64M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 10.05% |
| Net Income | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M | -32.91M | 172.92M |
| Net Margin % | - | - | - | - | - | - | -1307.11% | 5151.03% |
| Net Income Growth % | -135.54% | -193.37% | 110.92% | -631.85% | 5.54% | -69.04% | -119.03% | - |
| Net Income (Continuing) | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M | -32.91M | 160.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 17.09M | 11.12M | 5.04M | 1.28M |
| EPS (Diluted) | -4.97 | -3.95 | 72.93 | -4.99 | -27.25 | -31.73 | -547.60 | 1481.04 |
| EPS Growth % | -101.69% | -105.42% | 1561.52% | 81.69% | 14.12% | 94.21% | -136.97% | - |
| EPS (Basic) | - | -3.95 | 77.74 | -4.99 | -27.25 | -31.73 | -547.60 | 1495.96 |
| Diluted Shares Outstanding | 12.11M | 9.92M | 575.95K | 77.07M | 1.93M | 1.75M | 91.62K | 92.3K |
| Basic Shares Outstanding | 12.11M | 9.92M | 575K | 77.07M | 1.93M | 1.75M | 60K | 116K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by recent financial filings, AEON's cost structure remains entirely dominated by non-discretionary R&D expenditures, which reached $2.0 million in 2026Q1, reflecting the capital-intensive nature of advancing the ABP-450 pipeline without any offsetting commercial revenue to mitigate the ongoing operational burn.
The company's expense profile is characterized by high fixed costs associated with clinical trial execution, which appear to be the primary driver of the persistent operating losses. Investors should note that the lack of revenue generation means these R&D outlays directly deplete the company's limited cash reserves, leaving little room for operational error.
Based on reported income statements, AEON has experienced extreme EPS volatility, including a massive $304.00 per share gain in 2024Q2, which appears to be a non-operating anomaly rather than a reflection of sustainable core business performance or underlying profitability improvements.
The erratic swings in net income suggest that historical figures are heavily influenced by non-recurring items, which obscures the true underlying burn rate of the business. Analysts should focus on the consistent negative operating income trend rather than the headline net income figures, which may be distorted by accounting adjustments.
According to the provided income statement data, AEON lacks any meaningful operating leverage, as the company continues to report negative operating margins in every period, with 2026Q1 operating losses reaching $5.9 million while revenue remains at zero.
The absence of revenue prevents the realization of any economies of scale, meaning that SG&A and R&D costs continue to scale independently of commercial progress. This suggests that the company's current operating model is entirely dependent on external capital infusions to sustain its ongoing research activities.
As reported in financial statements, the company's cash position of approximately $3 million creates a precarious environment, suggesting that AEON may face significant challenges in funding its late-stage clinical programs without resorting to highly dilutive equity financing in the near term.
The current liquidity profile appears insufficient to support the long-term capital requirements of a biotechnology firm, raising questions about the company's ability to reach critical clinical milestones. Investors should monitor the potential for a 'going concern' risk, as the current burn rate significantly outpaces the available cash on hand.
Quick answers to the most common questions about buying AEON stock.
For fiscal year 2025, AEON Biopharma, Inc. (AEON) reported total revenue of $0.0M. This represents a 100.0% decline compared to $3.4M in 2019.
AEON Biopharma, Inc. (AEON) reported a net loss of $39.2M for the fiscal year ending 2025.